Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
BCLI Brainstorm Cell Therapeutics Inc. daily Stock Chart
BCLI [NASD]
Brainstorm Cell Therapeutics Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.42 Insider Own1.40% Shs Outstand20.36M Perf Week1.48%
Market Cap83.68M Forward P/E- EPS next Y-0.39 Insider Trans0.80% Shs Float18.16M Perf Month5.93%
Income-8.30M PEG- EPS next Q-0.14 Inst Own12.20% Short Float5.74% Perf Quarter35.64%
Sales- P/S- EPS this Y1.20% Inst Trans3.20% Short Ratio15.12 Perf Half Y3.79%
Book/sh0.48 P/B8.56 EPS next Y31.60% ROA-59.60% Target Price10.50 Perf Year27.61%
Cash/sh0.54 P/C7.68 EPS next 5Y- ROE-101.80% 52W Range2.92 - 5.35 Perf YTD15.77%
Dividend- P/FCF- EPS past 5Y6.70% ROI- 52W High-23.18% Beta1.32
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low40.75% ATR0.09
Employees24 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)68.30 Volatility1.84% 2.03%
OptionableYes Debt/Eq0.00 EPS Q/Q-19.70% Profit Margin- Rel Volume1.64 Prev Close4.04
ShortableYes LT Debt/Eq0.00 EarningsApr 04 BMO Payout- Avg Volume68.98K Price4.11
Recom2.00 SMA203.46% SMA508.87% SMA2009.68% Volume113,170 Change1.73%
Dec-19-16Reiterated Maxim Group Buy $5 → $6
Dec-22-15Reiterated Maxim Group Buy $14 → $5
Mar-18-19 10:26PM  Atlas Blockchain Announces Definitive Agreement for the Acquisition of Isracann and Amendment to Investor Services Agreement GlobeNewswire
Mar-15-19 10:50AM  BCLI: Hospital Exemption Approved in Israel; First Patient Enrolled in Phase 2 Study in Progressive MS Zacks Small Cap Research
Mar-14-19 01:00AM  BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS GlobeNewswire
Mar-13-19 11:57AM  Breakeven On The Horizon For Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Simply Wall St.
Mar-12-19 07:47AM  The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug Benzinga
Mar-07-19 04:00AM  BrainStorm to Host Business Update Conference Call GlobeNewswire
Feb-22-19 07:30AM  BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study GlobeNewswire
Feb-21-19 06:00AM  BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland GlobeNewswire
Feb-19-19 08:06AM  BrainStorm Issues a Statement to Patients and Shareholders GlobeNewswire
Feb-04-19 08:22AM  BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium GlobeNewswire
Jan-25-19 07:15AM  BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida GlobeNewswire
Jan-22-19 08:40AM  BrainStorm Granted Additional Patent for NurOwn® in Israel GlobeNewswire
Jan-11-19 12:05AM  BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA GlobeNewswire
Jan-07-19 01:30PM  BCLI: Initiating Phase 2 Study in Progressive Multiple Sclerosis Zacks Small Cap Research
Jan-03-19 06:04AM  BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week GlobeNewswire
Dec-27-18 07:35AM  BrainStorm Issues 2018 Letter to Shareholders GlobeNewswire
Dec-26-18 01:00AM  BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial GlobeNewswire
Dec-17-18 07:34AM  FDA Accepts BrainStorms NurOwn® IND Application for Progressive Multiple Sclerosis GlobeNewswire
07:21AM  BrainStorm gets FDA okay for stem cell trial in MS patients Reuters
Dec-04-18 08:00AM  BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND GlobeNewswire
Dec-03-18 01:53PM  Do Institutions Own Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Shares? Simply Wall St.
Nov-21-18 08:30AM  Detailed Research: Economic Perspectives on Stellar Biotechnologies, MAM Software Group, EverQuote, Brainstorm Cell Therapeutics, Mid-Con Energy Partners, LP, and Staffing 360 Solutions What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-19-18 08:00AM  BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis GlobeNewswire
Nov-07-18 08:00AM  BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences GlobeNewswire
Oct-30-18 10:15AM  BCLI: Phase 3 Trial to Be Fully Enrolled by Mid-2019 Zacks Small Cap Research
Oct-29-18 08:00AM  BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update GlobeNewswire
Oct-17-18 08:30AM  BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29 GlobeNewswire
Oct-04-18 11:23AM  Does Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Fall With The Market? Simply Wall St.
Oct-03-18 06:10AM  BrainStorm Highlights Translational Data and Presentations Supporting NUROWN® Technology Platform as a Best-In-Class Strategy in ALS GlobeNewswire
Sep-13-18 07:30AM  BrainStorm Granted New U.S. Patent for Industrial Scale Manufacturing of NurOwn® GlobeNewswire
Sep-12-18 08:49AM  BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn® Cellular Therapy Platform GlobeNewswire
Sep-05-18 11:36AM  BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference GlobeNewswire
Sep-04-18 08:00AM  BrainStorm Appoints Arturo Araya as Chief Commercial Officer GlobeNewswire
Aug-29-18 08:00AM  BrainStorm Cell Therapeutics to Provide Corporate Update at the H.C. Wainwright & Co 20th Annual Investor Conference GlobeNewswire
Aug-23-18 10:45AM  BCLI: Positive Interim Safety Analysis for Phase 3 Trial Zacks Small Cap Research
08:20AM  BrainStorm Cell Therapeutics Announces Successful Interim Safety Analysis in Phase 3 Trial of NurOwn® Therapy for ALS GlobeNewswire
Jul-25-18 09:03AM  BrainStorm Announces Grant of a New European Patent for NurOwn® PR Newswire
Jul-24-18 10:05AM  BCLI: Phase 3 Trial in ALS Fully Funded; Company to Announced Additional Indications for NurOwn Zacks Small Cap Research
Jul-23-18 08:00AM  BrainStorm Announces Financial Results for the Second Quarter of 2018 and Provides a Corporate Update PR Newswire
06:30AM  Brainstorm Cell Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Jul-17-18 08:32AM  BrainStorm to Announce Second Quarter Financial Results of 2018 and Provide a Corporate Update on Monday July 23 PR Newswire
Jul-05-18 09:40AM  BCLI: Additional Manufacturing Facility Secured for Phase 3 ALS Trial Zacks Small Cap Research +6.31%
07:30AM  BrainStorm Granted Japanese Patent for NurOwn® PR Newswire
07:20AM  Meet the one patient who will get access to this experimental ALS therapy before its approved MarketWatch
Jul-02-18 07:41AM  BrainStorm Announces Second U.S. Manufacturing Site for NurOwn® Production PR Newswire
Jun-28-18 05:00AM  BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello PR Newswire
Jun-26-18 08:05AM  BrainStorm Provides Update on "Right to Try" Policy PR Newswire
Jun-25-18 09:46AM  BrainStorm to Host Tomorrow a Conference Call to Announce Its "Right To Try" Policy PR Newswire
Jun-20-18 01:44PM  The Right to Try Could Cost Dying Patients a Fortune Bloomberg
Jun-13-18 09:06AM  Biotech Executives Fret Over Hassles And Uncertainties Of 'Right To Try' Forbes
Jun-11-18 10:20AM  BCLI: Determining Path Forward Following Right to Try; Warrant Exercise Raises $12.3M Zacks Small Cap Research
Jun-07-18 08:00AM  BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 Share PR Newswire -8.72%
Jun-02-18 06:34PM  Should You Worry About Brainstorm Cell Therapeutics Incs (NASDAQ:BCLI) CEO Pay? Simply Wall St.
Jun-01-18 07:50AM  BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill Signing PR Newswire
May-30-18 01:25AM  BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International Convention PR Newswire
May-25-18 09:19AM  BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation PR Newswire +6.22%
May-17-18 11:00AM  BCLI: Enrollment in Phase 3 Trial of NurOwn® Continuing on Schedule Zacks Small Cap Research
May-14-18 11:31AM  What Should Investors Know About Brainstorm Cell Therapeutics Incs (NASDAQ:BCLI) Future? Simply Wall St.
08:00AM  BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights PR Newswire
06:15AM  Brainstorm Cell Therapeutics Inc. to Host Earnings Call ACCESSWIRE
May-09-18 01:00AM  BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in London PR Newswire
May-08-18 08:30AM  Today's Research Reports on Trending Tickers: Cel-Sci Corporation and Brainstorm Cell Therapeutics ACCESSWIRE
07:12AM  Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14 PR Newswire
May-01-18 09:01AM  BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference PR Newswire
Apr-11-18 01:00AM  BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York PR Newswire
Mar-28-18 05:54AM  BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients PR Newswire
Mar-21-18 08:00AM  BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board PR Newswire
Mar-15-18 12:27PM  BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum PR Newswire
Mar-13-18 12:00PM  BCLI: Phase 3 Trial in ALS Enrolling Patients Zacks Small Cap Research
07:32AM  Innovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical Officer GlobeNewswire
Mar-12-18 01:00AM  BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair PR Newswire
Mar-08-18 06:45AM  Brainstorm Cell Therapeutics Inc. to Host Earnings Call ACCESSWIRE
06:30AM  BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017 PR Newswire
Mar-06-18 08:34AM  ALS patient group unhappy with how $115 million raised by the Ice Bucket Challenge is being spent MarketWatch
Mar-05-18 08:10AM  BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8 PR Newswire
Feb-07-18 06:12AM  BrainStorm's NurOwn® Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, California PR Newswire
Feb-06-18 05:35AM  BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor Conference PR Newswire
Feb-05-18 06:01AM  BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors PR Newswire -5.12%
Jan-16-18 06:00AM  BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22 PR Newswire
Jan-04-18 11:00AM  BCLI: Receives GMP Certification for NurOwn® Manufacturing Facility; Ready to Seek Approval Under Hospital Exemption in Israel Zacks Small Cap Research -5.04%
Jan-03-18 07:42AM  BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn® PR Newswire
Dec-29-17 03:54AM  Brainstorm Issues 2017 Letter to Shareholders PR Newswire +29.37%
Dec-20-17 05:16AM  BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase PR Newswire
Nov-29-17 06:29AM  BrainStorm's Abstracts on Phase 2 NurOwn® Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston PR Newswire
Nov-09-17 07:30AM  New Peer Reviewed Publication Shows That BrainStorm's NurOwn® Has a Unique miRNA Signature PR Newswire
Nov-02-17 09:03AM  BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer PR Newswire
Oct-23-17 09:29AM  BrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn® Technology for Parkinson's Disease And ALS PR Newswire
Oct-20-17 07:20AM  Corporate News Blog - Novan Acquires Intellectual Property Rights for Treating Viral Malignancies with Nitric Oxide ACCESSWIRE
Oct-19-17 07:10AM  Featured Company News - Syndax Pharma Signs Worldwide License Agreement for Allergan's Portfolio of Menin-MLL Inhibitors ACCESSWIRE
Oct-17-17 03:30PM  BCLI: Initiates Phase 3 Clinical Trial of NurOwn® in ALS Zacks Small Cap Research
07:00AM  BrainStorm Announces Third Quarter 2017 Financial Results PR Newswire
06:30AM  Investor Network: Brainstorm Cell Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Oct-16-17 12:40AM  BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS PR Newswire
12:05AM  BrainStorm enrolls first patients in advanced ALS stem cell trial Reuters
Oct-03-17 04:10PM  Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17 PR Newswire
Sep-27-17 03:34AM  BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital PR Newswire
Aug-23-17 01:00PM  BCLI: Phase 3 Trial of NurOwn® to Initiate Soon Zacks Small Cap Research
Aug-16-17 06:55AM  Investor Network: Brainstorm Cell Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Aug-15-17 01:00AM  BrainStorm Announces Second Quarter 2017 Financial Results PR Newswire
Aug-14-17 04:30PM  BrainStorm Announces Second Quarter 2017 Financial Results PR Newswire
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Almenoff June SherieDirectorJan 04Buy3.391,4755,0007,175Jan 08 09:00 AM
open in yahoo | open in reuters | open in google